Davern Capital Partners’s Pfizer PFE Stock Holding History

Davern Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,593,942	Closed	-$44.8M	–	19
2026 Q1	$44.8M	Sell	1,593,942 -448,300	-22%	-$11.9M	12.28%	1
2025 Q4	$50.9M	Buy	+2,042,242	New	+$51.5M	16.44%	1

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Davern Capital Partners's PFE Position: Q2 2026 in Review

Davern Capital Partners sold out of Pfizer (PFE) in Q2 2026, closing a stake of 1,593,942 shares — an estimated $44.8M sold.

Davern Capital Partners first reported a position in PFE in Q4 2025 and held it in 2 quarters. The position peaked at $50.9M in Q4 2025. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Davern Capital Partners reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
Davern Capital Partners sold 1,593,942 Pfizer shares in Q2 2026, an estimated $44.8M.
Davern Capital Partners first reported a position in Pfizer in Q4 2025 and held it in 2 quarters.
Davern Capital Partners's Pfizer position peaked at $50.9M in Q4 2025.
2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Davern Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.